35 Sjogren et al36 examined the utility of quantitative SPECT in several dementia subtypes. In each of the reported measurements, specificity was arbitrarily set at 85%. In subjects with frontotemporal dementia, maximal sensitivity/specificity achieved was 81%/85%, examining the rCBF of the superior frontal gyrus. In early-stage AD, measurement of rCBF of the MTL results in sensitivity Inhibitors,research,lifescience,medical of 85%. This measurement VRT752271 improved to 96% for subjects with late-stage AD. Interestingly, measurement of rCBF of the PTC results in sensitivity of 90% for dementia associated with subcortical white matter disease. Measurements of blood

flow in other brain structures such as white matter, hippocampus, or structures not affected in the particular dementia under study, resulted in diagnostic sensitivity often far below 80%,

and are not included in this review. Table V. Sensitivity and specificity of single photon emission computed Inhibitors,research,lifescience,medical tomography measures. AD, Alzheimer’s disease; NINCDS, NINCDS (National Institutes of Neurological, Communicative Disorders and Stroke) probable AD (clinical); Other, other neuropathological … Discussion Neuroimaging is fairly expensive, complex, and Inhibitors,research,lifescience,medical requires specialized facilities and expertise that may not always be easily available. Its routine use thus requires rational examination of cost-benefit considerations. For the purpose of AD diagnosis, the recent Academy of Neurology report9 concludes – and this review supports – that clinical diagnosis can be quite effective. In the most skilled hands and under favorable conditions, the accuracy of clinical diagnosis can be very high, as confirmed by histopathologic diagnosis. Inhibitors,research,lifescience,medical Sensitivity and specificity data of 85% or better are commonly reported. Therefore, the routine use of neuroimaging

was not recommended by the recent Academy report, nor does it appear justified by our data. While it may be premature to recommend neuroimaging in all evaluations of dementia, there is a clear role Inhibitors,research,lifescience,medical for neuroimaging in certain circumstances and, as such, neuroimaging may play a role in offering true, objective determinations of the whatever disease state. We agree with the conclusion that neuroimaging offers, at best, the same level of diagnostic accuracy as expert clinical assessment. Thus, from a cost-effectiveness viewpoint, neuroimaging currently offers no additional benefit over intensive, clinically based assessments. One must consider, however, that clinical assessment requires a level of expertise, as well as optimal circumstances for test administration that may not always be possible. Additionally, there are confounding circumstances compromising the validity and accuracy of clinical assessment. Three sets of observations suggest that neuroimaging should be considered, and offers favorable cost-benefit ratio, in some circumstances.